Phase III TAGS trial of Lonsurf in gastric cancer published in The Lancet Oncology.- Taiho Oncology.
Taiho Oncology announced the clinical data from the pivotal Phase III (TAGS) trial evaluating Lonsurf (trifluridine/tipiracil, TAS-102) versus placebo and best supportive care in patients with heavily pretreated metastatic gastric/gastroesophageal junction (GEJ) cancers who have progressed or are intolerant to previous lines of therapy were published in The Lancet Oncology. In the TAGS trial, patients treated with Lonsurf showed a clinically meaningful and statistically significant improvement in OS compared with placebo, a 31 percent risk reduction of death (HR 0.69 one sided p=0.00029), which translated into a prolongation of median survival of 2.1 months (5.7 months for trifluridine/tipiracil versus 3.6 months for placebo).
In addition, Lonsurf demonstrated a statistically significant improvement in PFS and time to deterioration of ECOG performance status versus placebo, as well as a predictable and manageable safety profile consistent with that previously reported in patients with metastatic colorectal cancer.
See: "Trifluridine/tipiracil versus placebo in patients with heavily pretreated metastatic gastric cancer (TAGS): a randomised, double-blind, placebo-controlled, phase III trial." Kohei Shitara et al. The Lancet Oncology October 21, 2018DOI:https://doi.org/10.1016/S1470-2045(18)30739-3
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.